Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
Several other research analysts have also issued reports on the company. ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright initiated coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 20th. They issued a “neutral” rating and a $0.50 price target on the stock. Five analysts have rated the stock with a hold rating, Sunesis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $2.00.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. On average, research analysts anticipate that Sunesis Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.